<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998477</url>
  </required_header>
  <id_info>
    <org_study_id>V58P15</org_study_id>
    <secondary_id>2013-002080-26</secondary_id>
    <nct_id>NCT01998477</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to &lt;18 Years of Age at Risk for Influenza-Related Complications</brief_title>
  <official_title>A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to &lt;18 Years of Age at Risk for Influenza-Related Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to &lt; 18
      years of age who are at risk of complications of influenza disease due to underlying
      diseases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group</measure>
    <time_frame>Day 1 through Day 7 post injection 1 and Day 29 through Day 35 post injection 2</time_frame>
    <description>Safety was assessed in terms of number of the subjects (3 to &lt; 18 years of age) who reported solicited local, systemic AEs as well as other solicited AEs after receiving one or two doses of either TIVc or TIV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events (AEs), Following Vaccination With Either TIVc or TIV by Age Sub-strata</measure>
    <time_frame>Day 1 through Day 7 after any vaccination</time_frame>
    <description>Safety was assessed in terms of number of the subjects (3 to &lt;6 years,(≥ 6 to &lt; 9 years and 9 to &lt;18 Years of age) who reported solicited local, systemic AEs as well as other solicited AEs after receiving one or two doses of either TIVc or TIV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events Following Vaccination With Either TIVc or TIV by Overall Age Group and Age Sub-strata</measure>
    <time_frame>Day 1 -Day 181(one dose group) Day 1 -Day 209(two dose group)</time_frame>
    <description>Safety was assessed in terms of number of subjects who reported any unsolicited AEs (four weeks after 1st vaccination and up to three weeks after 2nd vaccination), serious adverse events (SAEs), new onset of chronic diseases (NOCD), medically attended AEs and AEs leading to vaccine/study withdrawal after receiving one or two doses of either TIVc or TIV by overall age group (3 to &lt;18 years) and age sub-strata (3 to &lt;9 years and 9 to &lt;18 years)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TIVc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flu vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIVc</intervention_name>
    <description>Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain [A/H1N1-like, A/H3N2-like, and B-like]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere</description>
    <arm_group_label>TIVc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV</intervention_name>
    <description>A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain [A/ H1N1-like, A/H3N2-like, and B-like]) IM injection recommended by the WHO for the 2013‑2014 influenza season in the Northern Hemisphere.</description>
    <arm_group_label>TIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals 3 to &lt;18 years of age with underlying medical conditions that indicate an
             increased risk of complications from influenza infection.

          -  Further eligibility criteria may be discussed by contacting the site(s)

        Exclusion Criteria:

          -  Individuals with any fatal prognosis of an underlying medical condition (&lt;12 month
             life expectancy).

          -  Individuals hospitalized at the time of enrolment.

          -  Individuals with a history of any anaphylaxis, serious vaccine reactions, or
             hypersensitivity to any of the vaccine components.

          -  Further eligibility criteria may be discussed by contacting the site(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigational Site 022</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 020</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 021</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 023</name>
      <address>
        <city>Roma</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 031</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 017</name>
      <address>
        <city>Burriana</city>
        <state>Castellon</state>
        <zip>12530</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 016</name>
      <address>
        <city>Castellon de la Plana</city>
        <state>Castellon</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 010</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 015</name>
      <address>
        <city>L'Eliana</city>
        <state>Valencia</state>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 013</name>
      <address>
        <city>Paiporta</city>
        <state>Valencia</state>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 018</name>
      <address>
        <city>Quart de Poblet</city>
        <state>Valencia</state>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 030</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 011</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 019</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 014</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site 012</name>
      <address>
        <city>Valencia</city>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2013</study_first_posted>
  <results_first_submitted>January 16, 2015</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Flu</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 12 centers in Spain and 4 centers from Italy.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TIVc (3 to &lt;18 Years)</title>
          <description>Vaccine naive and non-naïve subjects received one or two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
        </group>
        <group group_id="P2">
          <title>TIV (3 to &lt;18 Years)</title>
          <description>Vaccine naive and non-naïve subjects received one or two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TIVc (3 to &lt;18 Years)</title>
          <description>Vaccine naive and non-naïve subjects received one or two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
        </group>
        <group group_id="B2">
          <title>TIV (3 to &lt;18 Years)</title>
          <description>Vaccine naive and non-naïve subjects received one or two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="282"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="430"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="4.0"/>
                    <measurement group_id="B2" value="9.0" spread="3.9"/>
                    <measurement group_id="B3" value="8.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FEMALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group</title>
        <description>Safety was assessed in terms of number of the subjects (3 to &lt; 18 years of age) who reported solicited local, systemic AEs as well as other solicited AEs after receiving one or two doses of either TIVc or TIV</description>
        <time_frame>Day 1 through Day 7 post injection 1 and Day 29 through Day 35 post injection 2</time_frame>
        <population>Analysis was done on safety dataset, i.e. the subjects in the Exposed Set who provided post-vaccination solicited AE data</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc _inj 1 (3 to &lt;18 Years)</title>
            <description>Vaccine naive and non-naïve subjects received one or two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIVc_inj 2 (3 to &lt;18 Years)</title>
            <description>Vaccine naive and non-naïve subjects received one or two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIV_inj 1 (3 to &lt;18 Years)</title>
            <description>Vaccine naïve and non-naive subjects received one or two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O4">
            <title>TIV_inj 2 (3 to &lt;18 Years)</title>
            <description>Vaccine naïve and non-naive subjects received one or two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group</title>
          <description>Safety was assessed in terms of number of the subjects (3 to &lt; 18 years of age) who reported solicited local, systemic AEs as well as other solicited AEs after receiving one or two doses of either TIVc or TIV</description>
          <population>Analysis was done on safety dataset, i.e. the subjects in the Exposed Set who provided post-vaccination solicited AE data</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema ,&lt; 6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration &lt; 6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis &lt; 6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema &gt;=6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration &gt;=6years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis &gt;= 6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of pain and or fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevention of pain and or fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events (AEs), Following Vaccination With Either TIVc or TIV by Age Sub-strata</title>
        <description>Safety was assessed in terms of number of the subjects (3 to &lt;6 years,(≥ 6 to &lt; 9 years and 9 to &lt;18 Years of age) who reported solicited local, systemic AEs as well as other solicited AEs after receiving one or two doses of either TIVc or TIV</description>
        <time_frame>Day 1 through Day 7 after any vaccination</time_frame>
        <population>Analysis was done on safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc_Non naive_inj 1 (3 to &lt;6 Years)</title>
            <description>Vaccine non-naïve subjects received one dose of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIVc_naive_inj 1 (3 to &lt;6 Years)</title>
            <description>Vaccine naïve subjects received two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIVc_naive_inj 2 (3 to &lt;6 Years)</title>
            <description>Vaccine naïve subjects received two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O4">
            <title>TIV_Non naive_inj 1 (3 to &lt;6 Years)</title>
            <description>Vaccine nonnaïve subjects received one dose of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O5">
            <title>TIV_naive_inj 1 (3 to &lt;6 Years)</title>
            <description>Vaccine naïve subjects received two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O6">
            <title>TIV_naive_inj 2 (3 to &lt;6 Years)</title>
            <description>Vaccine naïve subjects received two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O7">
            <title>TIVc_Non naive_Inj 1 (≥ 6 to &lt; 9 Years)</title>
            <description>Vaccine non-naïve subjects received one dose of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O8">
            <title>TIVc_Naive_inj 1 (≥ 6 to &lt; 9 Years)</title>
            <description>Vaccine naïve subjects received two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O9">
            <title>TIVc_Naive_inj 2 (≥ 6 to &lt; 9 Years)</title>
            <description>Vaccine naïve subjects received two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O10">
            <title>TIV_Non Naive_inj 1 (≥ 6 to &lt; 9 Years)</title>
            <description>Vaccine non-naïve subjects received one dose of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O11">
            <title>TIV_Naive_inj 1 (≥ 6 to &lt; 9 Years)</title>
            <description>Vaccine naïve subjects received two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O12">
            <title>TIV_Naive_inj 2 (≥ 6 to &lt; 9 Years)</title>
            <description>Vaccine naïve subjects received two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O13">
            <title>TIVc_Non Naive (9 to &lt;18 Years)</title>
            <description>Vaccine nonnaïve subjects received one dose of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O14">
            <title>TIV_Non Naive (9 to &lt;18 Years)</title>
            <description>Vaccine nonnaïve subjects received one dose of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events (AEs), Following Vaccination With Either TIVc or TIV by Age Sub-strata</title>
          <description>Safety was assessed in terms of number of the subjects (3 to &lt;6 years,(≥ 6 to &lt; 9 years and 9 to &lt;18 Years of age) who reported solicited local, systemic AEs as well as other solicited AEs after receiving one or two doses of either TIVc or TIV</description>
          <population>Analysis was done on safety dataset</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="33"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="23"/>
                <count group_id="O12" value="24"/>
                <count group_id="O13" value="138"/>
                <count group_id="O14" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="13"/>
                    <measurement group_id="O12" value="11"/>
                    <measurement group_id="O13" value="81"/>
                    <measurement group_id="O14" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness(N=28,49,49,19,15,15,0,0,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain(N=0,0,0,0,0,0,26,32,31,16,22,22,138,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="8"/>
                    <measurement group_id="O13" value="73"/>
                    <measurement group_id="O14" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema27,50,50,18,15,15,26,34,32,16,23,23,131,61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="6"/>
                    <measurement group_id="O14" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="58"/>
                    <measurement group_id="O14" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills28,50,48,19,15,14,25,33,31,16,22,23,138,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="19"/>
                    <measurement group_id="O14" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea28,50,50,19,14,15,26,33,31,16,22,23,137,71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="11"/>
                    <measurement group_id="O14" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness(N=28,49,48,19,15,15,0,0,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting28,50,50,19,15,15,26,33,31,16,22,23,138,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="8"/>
                    <measurement group_id="O14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia 0,0,0,0,0,0,26,32,30,16,20,21,136,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="18"/>
                    <measurement group_id="O14" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue 0,0,0,0,0,0,26,32,30,16,20,21,137,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="23"/>
                    <measurement group_id="O14" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache0,0,0,0,0,0,26,32,30,16,20,21,138,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="29"/>
                    <measurement group_id="O14" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss appetite 0,0,0,0,0,0,26,32,31,16,22,23,138,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="20"/>
                    <measurement group_id="O14" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia0,0,0,0,0,0,26,32,30,16,20,21,138,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="29"/>
                    <measurement group_id="O14" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea 0,0,0,0,0,0,26,32,30,16,20,21,137,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="17"/>
                    <measurement group_id="O14" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temp. ( &gt;= 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="4"/>
                    <measurement group_id="O14" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment of pain and or fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="9"/>
                    <measurement group_id="O14" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events Following Vaccination With Either TIVc or TIV by Overall Age Group and Age Sub-strata</title>
        <description>Safety was assessed in terms of number of subjects who reported any unsolicited AEs (four weeks after 1st vaccination and up to three weeks after 2nd vaccination), serious adverse events (SAEs), new onset of chronic diseases (NOCD), medically attended AEs and AEs leading to vaccine/study withdrawal after receiving one or two doses of either TIVc or TIV by overall age group (3 to &lt;18 years) and age sub-strata (3 to &lt;9 years and 9 to &lt;18 years)</description>
        <time_frame>Day 1 –Day 181(one dose group) Day 1 –Day 209(two dose group)</time_frame>
        <population>Analysis was done on unsolicited safety dataset, i.e. all subjects in the Exposed Set who have post-vaccination unsolicited AE records (even if no AEs have occurred)</population>
        <group_list>
          <group group_id="O1">
            <title>TIVc (3 to &lt;18 Years)</title>
            <description>Vaccine naïve and non-naive subjects received one or two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV (3 to &lt;18 Years)</title>
            <description>Vaccine naïve and non-naive subjects received one or two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O3">
            <title>TIVc_Naive (3 to &lt;9 Years)</title>
            <description>Vaccine naïve subjects received one dose of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O4">
            <title>TIVc_Non Naive (3 to &lt;9 Years)</title>
            <description>Vaccine non naïve subjects received one dose of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O5">
            <title>TIVc_Non Naive (9 to &lt;18 Years)</title>
            <description>Vaccine nonnaïve subjects received one dose of cell culture derived trivalent subunit influenza vaccine formulation (TIVc)</description>
          </group>
          <group group_id="O6">
            <title>TIV_Naive (3 to &lt;9 Years)</title>
            <description>Vaccine naïve subjects received one dose of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O7">
            <title>TIV_Non Naive (3 to &lt;9 Years)</title>
            <description>Vaccine non naïve subjects received one dose of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
          <group group_id="O8">
            <title>TIV_Non Naive (9 to &lt;18 Years)</title>
            <description>Vaccine nonnaïve subjects received one dose of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events Following Vaccination With Either TIVc or TIV by Overall Age Group and Age Sub-strata</title>
          <description>Safety was assessed in terms of number of subjects who reported any unsolicited AEs (four weeks after 1st vaccination and up to three weeks after 2nd vaccination), serious adverse events (SAEs), new onset of chronic diseases (NOCD), medically attended AEs and AEs leading to vaccine/study withdrawal after receiving one or two doses of either TIVc or TIV by overall age group (3 to &lt;18 years) and age sub-strata (3 to &lt;9 years and 9 to &lt;18 years)</description>
          <population>Analysis was done on unsolicited safety dataset, i.e. all subjects in the Exposed Set who have post-vaccination unsolicited AE records (even if no AEs have occurred)</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="139"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any possibly related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or probably related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically Attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to vaccine/study withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local,systemic AEs collected -day 1 through Day 7 post injection 1 and Day 29 through Day 35 post injection 2, unsolicited AEs -Day 1 through Day 29 post 1st vaccination and Day 29 to Day 57 post 2nd vaccination. SAEs Day 1 through end of study</time_frame>
      <desc>Subjects 9 to &lt;18 years of age were determined to be “previously vaccinated (vaccine non-naive)” by default. Analysis was done on unsolicited safety set-All subjects in the exposed set who had postvaccination unsolicited AE records (even if no AEs were reported).</desc>
      <group_list>
        <group group_id="E1">
          <title>TIVc (3 to &lt;18 Years)</title>
          <description>Vaccine naive and non-naïve subjects received one or two doses of cell culture derived trivalent subunit influenza vaccine formulation (TIVc).</description>
        </group>
        <group group_id="E2">
          <title>TIV (3 to &lt;18 Years)</title>
          <description>Vaccine naive and non-naïve subjects received one or two doses of egg derived trivalent subunit influenza vaccine formulation (TIV)</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total Number of subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>SICKLE CELL ANAEMIA WITH CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>PHARYNGOTONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COMPLEX PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>TOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMATIC CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="372" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="233" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMATIC CRISIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="426"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="426"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

